Clinical Trial Update: A Randomized Trial of rhTPO Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia [Phase 2, Phase 3]

View source ↗

Summary

A randomized trial compares rhTPO to placebo for thrombocytopenia in patients with Low/Intermediate-1 risk myelodysplastic syndrome (MDS). Phase 2/3 study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• rhTPO (recombinant human thrombopoietin)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Low/Intermediate Risk-1 MDS | Phase 2, Phase 3 | Status: UNKNOWN